Clinical Focus ›› 2021, Vol. 36 ›› Issue (9): 807-810.doi: 10.3969/j.issn.1004-583X.2021.09.009

Previous Articles     Next Articles

CT-guided percutaneous radiofrequency ablation for hepatic carcinoma

Guo Xiaojun, Kong Yanliang, Liu Tao(), Cheng Zhengxiang, Zhang Rui, Fan Lei   

  1. Department of Oncology, People's Hospital of Tongchuan, Tongchuan 727000, China
  • Received:2021-07-02 Online:2021-09-20 Published:2021-10-05
  • Contact: Liu Tao


Objective To investigate the efficacy of CT-guided percutaneous radiofrequency ablation(RFA) for hepatic malignancies(HM). Methods Totally 76 HM inpatients from March 2016 to October 2018 were randomly divided into observation group and control group, 38 patients in observation group treated with CT-guided percutaneous RFA and 38 patients in control group with transcatheter arterial chemoembolization(TACE). Follow-up lasted for more 24 months. The key observation was the objective remission rate (ORR) of posttreatment, 6-,12-, 24-month survival rate, 3-month tumor markers, and complications. Results The difference was statistic significance in ORR between observation group and control group after treatment(81.6% vs 57.9%, χ 2=5.814,P<0.05). Clinical effect was significantly better in observation group than in control group(Z=6.457, P<0.05). 12-, 24-month survival rate were significantly higher in observation group than in control group(P<0.05). Conclusion For HM patients, CT-guided percutaneous RFA has good short-term and long-term effect, with little pain.

Key words: liver neoplasms, radiofrequency ablation

CLC Number: